-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*Only for medical professionals to read for reference How does nasal spray fight the new coronavirus? On June 4, Nature magazine published an article stating that scientists have developed a nasal spray "assembled" antibody that can prevent and treat the new coronavirus
.
The research paper was originally titled "IgM nasal delivery can resist infection of new coronavirus variants".
The research team designed a new IgM antibody therapy that can have a strong neutralizing effect on more than 20 new coronavirus variants
.
Spraying into the nose of mice 6 hours before or 6 hours after infection can drastically reduce the amount of virus in the lungs within two days
.
New crown "nasal spray", "sucking" antibodies instead of "sucking" antigens.
Mentioning nasal sprays, the recent hot topic is the nasal spray/inhalation new crown vaccine jointly developed by the Chinese Academy of Engineering academician Chen Wei's team and Kang Xinuo
.
According to relevant information, the principle is to atomize the vaccine into tiny particles, which enter the respiratory tract and lungs through inhalation, thereby stimulating mucosal immunity
.
It is also "nebulized inhalation", "respiratory tract and lungs" and "mucosa".
The difference is that this is a brand new IgM antibody therapy designed by many overseas Chinese scientists
.
Antibody therapy is different from vaccines.
There is no need to stimulate the body to produce antibodies through antigens, but to "prescribe the right medicine" more directly.
Previously, it has achieved good results in the treatment of emerging and emerging infectious diseases such as Ebola and Zika.
.
Since the new coronavirus pandemic, scientists have also been developing antibodies
.
In October last year, former US President Trump announced that he had accepted Regeneron's antibody cocktail therapy after infection
.
But so far, almost all neutralizing monoclonal antibodies in clinical trials are IgG, which is difficult to effectively enter mucosal tissues.
After intravenous injection, the level of antibodies in the lung is 200-500 times lower than that of serum.
Even if the dose is increased, Its antiviral effect is still limited
.
What is the difference between "upgraded" assembled antibodies? In this study, the scientists worked hard on the route of administration
.
The respiratory tract is the main target of new coronavirus infection, and its viral load is related to severely ill patients
.
Using mice as the test subject, the researchers assembled five IgG antibodies (CoV2-06, 09, 12, 14, 16) and IgM antibodies.
The "upgraded" IgM-"X" antibody can be sprayed through the respiratory tract.
Medicine, spread and transport in mucosal parts, constitute the first line of defense against pathogens in mucosal tissues
.
This experiment focused on comparing IgG-14 and IgM-14 (IgM "embedded" in IgG-14)
.
After a single dose, the researchers tracked the distribution of antibodies in mice through in vitro imaging and found that IgM-14 lasted for at least 96 hours in whole-body imaging, mainly in the nasal cavity and lungs, and hardly appeared in the blood and other organs.
168 It can still be detected in the nasal cavity after hours
.
In terms of efficacy, studies have confirmed that IgM-14 has a stronger inhibitory ability.
Compared with IgG antibodies against the same epitope, it can inhibit the binding of the new coronavirus receptor binding region RBD to the ACE2 receptor more potently
.
Neutralization titration was performed on Vero and human A549 (A549-ACE2) cells overexpressing ACE2.
The neutralization titers (NT50) of IgM-14 were 0.
011nm and 0.
0028nm, which were 236 times and 571 times that of IgG-14.
.
The power against mutant strains is increased by a hundredfold.
The ability to fight against mutant viruses is undoubtedly the most eye-catching part of this experiment
.
Previously, emerging new variants of new coronaviruses are gradually becoming resistant to traditional IgG therapies
.
In November last year, Eli Lilly’s monoclonal antibody drug bamlanivimab was approved by the U.
S.
Food and Drug Administration (FDA) for emergency use authorization for the treatment of patients with new coronary pneumonia
.
But in March of this year, the FDA announced that it would stop the distribution of bamlanivimab as a monotherapy in multiple states, citing the continued increase in the number of new coronavirus variants that are resistant to drugs
.
As early as the research stage, the researchers scanned the antibody library of healthy people to screen for antibodies that can recognize the new coronavirus, and finally found two IgG antibodies: the combination of CoV2-06 and CoV2-14, which can better prevent The mutation of the virus escapes
.
After further transformation into IgM-"X", the researchers constructed a recombinant virus based on the US-WA1 strain and replaced its full spike gene with B.
1.
1.
7 (found in the UK) and P.
1 (found in Brazil) ) And B.
1.
351 (found in South Africa) mutant strains, and their "mutation resistance" ability was tested
.
The experimental results showed that IgM-14 effectively neutralized all three variants, and the neutralizing ability of B.
1.
1.
7, P.
1 and B.
1.
351 variants were 45 times, 547 times and 374 times that of IgG-14, respectively.
The ability to fight against mutant viruses is equivalent to that of the unmodified US-WA1 strain
.
At the same time, the researchers also produced 19 RBD mutants to characterize the efficacy of IgM-14 and IgG-14.
The test results found that among all RBD mutants, IgM-14 showed higher performance than IgG-14.
The RBD affinity and ACE2 blocking activity
.
In terms of dosage and safety, IgM-14 can play a role in the prevention and treatment of the new coronavirus in mice with a single nasal drop of 0.
044mg/kg and 0.
4mg/kg
.
After the mice were administered twice a day for 5 consecutive days, all the mice survived, and there was no change in body weight when the study was terminated
.
Currently, this drug is undergoing follow-up development and is expected to enter clinical trials in the third quarter of this year
.
In addition to significantly improving the efficacy and reducing drug resistance, researchers believe that once the therapy is proven to be available for clinical use, it will further simplify the prevention and treatment of new coronary pneumonia
.
.
The research paper was originally titled "IgM nasal delivery can resist infection of new coronavirus variants".
The research team designed a new IgM antibody therapy that can have a strong neutralizing effect on more than 20 new coronavirus variants
.
Spraying into the nose of mice 6 hours before or 6 hours after infection can drastically reduce the amount of virus in the lungs within two days
.
New crown "nasal spray", "sucking" antibodies instead of "sucking" antigens.
Mentioning nasal sprays, the recent hot topic is the nasal spray/inhalation new crown vaccine jointly developed by the Chinese Academy of Engineering academician Chen Wei's team and Kang Xinuo
.
According to relevant information, the principle is to atomize the vaccine into tiny particles, which enter the respiratory tract and lungs through inhalation, thereby stimulating mucosal immunity
.
It is also "nebulized inhalation", "respiratory tract and lungs" and "mucosa".
The difference is that this is a brand new IgM antibody therapy designed by many overseas Chinese scientists
.
Antibody therapy is different from vaccines.
There is no need to stimulate the body to produce antibodies through antigens, but to "prescribe the right medicine" more directly.
Previously, it has achieved good results in the treatment of emerging and emerging infectious diseases such as Ebola and Zika.
.
Since the new coronavirus pandemic, scientists have also been developing antibodies
.
In October last year, former US President Trump announced that he had accepted Regeneron's antibody cocktail therapy after infection
.
But so far, almost all neutralizing monoclonal antibodies in clinical trials are IgG, which is difficult to effectively enter mucosal tissues.
After intravenous injection, the level of antibodies in the lung is 200-500 times lower than that of serum.
Even if the dose is increased, Its antiviral effect is still limited
.
What is the difference between "upgraded" assembled antibodies? In this study, the scientists worked hard on the route of administration
.
The respiratory tract is the main target of new coronavirus infection, and its viral load is related to severely ill patients
.
Using mice as the test subject, the researchers assembled five IgG antibodies (CoV2-06, 09, 12, 14, 16) and IgM antibodies.
The "upgraded" IgM-"X" antibody can be sprayed through the respiratory tract.
Medicine, spread and transport in mucosal parts, constitute the first line of defense against pathogens in mucosal tissues
.
This experiment focused on comparing IgG-14 and IgM-14 (IgM "embedded" in IgG-14)
.
After a single dose, the researchers tracked the distribution of antibodies in mice through in vitro imaging and found that IgM-14 lasted for at least 96 hours in whole-body imaging, mainly in the nasal cavity and lungs, and hardly appeared in the blood and other organs.
168 It can still be detected in the nasal cavity after hours
.
In terms of efficacy, studies have confirmed that IgM-14 has a stronger inhibitory ability.
Compared with IgG antibodies against the same epitope, it can inhibit the binding of the new coronavirus receptor binding region RBD to the ACE2 receptor more potently
.
Neutralization titration was performed on Vero and human A549 (A549-ACE2) cells overexpressing ACE2.
The neutralization titers (NT50) of IgM-14 were 0.
011nm and 0.
0028nm, which were 236 times and 571 times that of IgG-14.
.
The power against mutant strains is increased by a hundredfold.
The ability to fight against mutant viruses is undoubtedly the most eye-catching part of this experiment
.
Previously, emerging new variants of new coronaviruses are gradually becoming resistant to traditional IgG therapies
.
In November last year, Eli Lilly’s monoclonal antibody drug bamlanivimab was approved by the U.
S.
Food and Drug Administration (FDA) for emergency use authorization for the treatment of patients with new coronary pneumonia
.
But in March of this year, the FDA announced that it would stop the distribution of bamlanivimab as a monotherapy in multiple states, citing the continued increase in the number of new coronavirus variants that are resistant to drugs
.
As early as the research stage, the researchers scanned the antibody library of healthy people to screen for antibodies that can recognize the new coronavirus, and finally found two IgG antibodies: the combination of CoV2-06 and CoV2-14, which can better prevent The mutation of the virus escapes
.
After further transformation into IgM-"X", the researchers constructed a recombinant virus based on the US-WA1 strain and replaced its full spike gene with B.
1.
1.
7 (found in the UK) and P.
1 (found in Brazil) ) And B.
1.
351 (found in South Africa) mutant strains, and their "mutation resistance" ability was tested
.
The experimental results showed that IgM-14 effectively neutralized all three variants, and the neutralizing ability of B.
1.
1.
7, P.
1 and B.
1.
351 variants were 45 times, 547 times and 374 times that of IgG-14, respectively.
The ability to fight against mutant viruses is equivalent to that of the unmodified US-WA1 strain
.
At the same time, the researchers also produced 19 RBD mutants to characterize the efficacy of IgM-14 and IgG-14.
The test results found that among all RBD mutants, IgM-14 showed higher performance than IgG-14.
The RBD affinity and ACE2 blocking activity
.
In terms of dosage and safety, IgM-14 can play a role in the prevention and treatment of the new coronavirus in mice with a single nasal drop of 0.
044mg/kg and 0.
4mg/kg
.
After the mice were administered twice a day for 5 consecutive days, all the mice survived, and there was no change in body weight when the study was terminated
.
Currently, this drug is undergoing follow-up development and is expected to enter clinical trials in the third quarter of this year
.
In addition to significantly improving the efficacy and reducing drug resistance, researchers believe that once the therapy is proven to be available for clinical use, it will further simplify the prevention and treatment of new coronary pneumonia
.
